Cargando…

Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review

The objective of this study was to critically review the cost-effectiveness (CE) of the recombinant zoster vaccine (RZV) against herpes zoster (HZ). A literature review was conducted in PubMed, Embase, and Cochrane between January 1, 2017, and February 28, 2022, and on select public healthcare agenc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giannelos, Nikolaos, Ng, Cheryl, Curran, Desmond
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Zoster
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054181/ https://www.ncbi.nlm.nih.gov/pubmed/36916240 http://dx.doi.org/10.1080/21645515.2023.2168952

Ejemplares similares

Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer
por: Curran, Desmond, et al.
Publicado: (2023)

Preclinical immunogenicity of an adenovirus-vectored vaccine for herpes zoster
por: Ulaszewska, Marta, et al.
Publicado: (2023)

The incidence of herpes zoster in China: A meta-analysis and evidence quality assessment
por: Zhang, Zhujiazi, et al.
Publicado: (2023)

Hospitalization burden related to herpes zoster infection during the COVID-19 pandemic in Spain (2020-2021)
por: Irigoyen-Mansilla, Victor-Manuel, et al.
Publicado: (2023)

Proceedings of the expert consensus group meeting on herpes zoster disease burden and prevention in India: An opinion paper
por: Ramasubramanian, V, et al.
Publicado: (2023)

How to manage herpes zoster ophthalmicus
por: Tuft, Stephen
Publicado: (2020)

How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be?
por: Han, Ru, et al.
Publicado: (2023)

Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults
por: Teng, Lida, et al.
Publicado: (2022)

Lifetime risk of herpes zoster in the population of Beijing, China
por: Lee, Christa, et al.
Publicado: (2023)

20. Cost-Effectiveness of Recombinant Zoster Vaccine for Vaccinating Immunocompromised Adults Against Herpes Zoster in the United States
por: Curran, Desmond, et al.
Publicado: (2021)

8. The Adjuvanted Recombinant Zoster Vaccine (RZV) Confers Long-term Protection Against Herpes Zoster: Interim Results of an Extension Study (ZOSTER-049) of Two Clinical Trials (ZOE-50 and ZOE-70)
por: Boutry, Céline, et al.
Publicado: (2020)

Public health impact of herpes zoster vaccination on older adults in Hong Kong
por: Chan, Paul K. S., et al.
Publicado: (2023)

Healthy ageing: Herpes zoster infection and the role of zoster vaccination
por: Curran, Desmond, et al.
Publicado: (2023)

114. Long-term Protection Against Herpes Zoster (HZ) by the Adjuvanted Recombinant Zoster Vaccine (RZV): Interim Efficacy, Immuno and Safety Results at Approximately 10 Years after Initial Vaccination
por: Strezova, Ana, et al.
Publicado: (2022)

Correction to: 114. Long-term Protection Against Herpes Zoster (HZ) by the Adjuvanted Recombinant Zoster Vaccine (RZV): Interim Efficacy, Immuno and Safety Results at Approximately 10 Years after Initial Vaccination
Publicado: (2023)

Healthy ageing: Herpes zoster infection and the role of the adjuvanted recombinant zoster vaccine
por: Curran, D, et al.
Publicado: (2022)

37. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine (RZV) in Immunocompromised Populations: an Overview of 6 Trials
por: Fauqued, Marta Lopez, et al.
Publicado: (2020)

Herpes Zoster Following Recombinant Zoster Vaccine With or Without Concomitant Vaccination
por: Bruxvoort, Katia J, et al.
Publicado: (2022)

07. Recombinant Zoster Vaccine (RZV) Second-Dose Completion in Adults Age 50‒64 Years in the United States
por: Leung, Jessica, et al.
Publicado: (2021)

Vaccine against herpes zoster
por: Pasternak, Jacyr
Publicado: (2013)

Cost-Effectiveness of Herpes Zoster Vaccination
por: Sriwijitalai, Won, et al.
Publicado: (2019)

26. Is There a Correlation Between Reactogenicity and Immune Responses of the Adjuvanted Recombinant Zoster Vaccine (RZV)? A Post-hoc Analysis
por: Callegaro, Andrea, et al.
Publicado: (2021)

Comment on “Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine”
por: Giannelos, Nikolaos, et al.
Publicado: (2022)

7. Can Recombinant Zoster Vaccine Administration Decrease the Use of Herpes Zoster-related Pain Medication Across Randomized Controlled Studies?
por: Kim, Joon Hyung, et al.
Publicado: (2020)

The temporal impact of aging on the burden of herpes zoster
por: Varghese, Lijoy, et al.
Publicado: (2017)

Herpes Zoster and Recurrent Herpes Zoster
por: Shiraki, Kimiyasu, et al.
Publicado: (2017)

Update on Recommendations for Use of Herpes Zoster Vaccine
por: Hales, Craig M., et al.
Publicado: (2014)

Adjuvanted recombinant zoster vaccine decreases herpes zoster-associated pain and the use of pain medication across 3 randomized, placebo-controlled trials
por: Kim, Joon Hyung, et al.
Publicado: (2023)

Herpes Zoster Vaccination
por: Kim, Kyung Hoon
Publicado: (2013)

Herpes Zoster Vaccines
por: Harbecke, Ruth, et al.
Publicado: (2021)

Herpes zoster ophthalmicus or Herpes zoster maxillaris?
por: Chandravanshi, Shivcharan Lal, et al.
Publicado: (2009)

Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live
por: Curran, Desmond, et al.
Publicado: (2019)

Recombinant zoster vaccine (Shingrix(®)): a new option for the prevention of herpes zoster and postherpetic neuralgia
por: Singh, Grisuna, et al.
Publicado: (2020)

Meta-Regression of Herpes Zoster Incidence Worldwide
por: Curran, Desmond, et al.
Publicado: (2021)

Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines
por: Marra, Yasmin, et al.
Publicado: (2022)

Status of Herpes Zoster and Herpes Zoster Vaccines in 2023: A position paper
por: García, José María Molero, et al.
Publicado: (2023)

Assessment of the potential public health impact of Herpes Zoster vaccination in Germany
por: Curran, Desmond, et al.
Publicado: (2017)

Herpes zoster vaccine in Korea
por: Choi, Won Suk
Publicado: (2013)

Recombinant varicella zoster virus glycoprotein E antigen vaccine for prevention of herpes zoster and postherpetic neuralgia
Publicado: (2021)

A Broad Safety Assessment of the Recombinant Herpes Zoster Vaccine
por: Yih, W Katherine, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f6l0ac0ppc8s2tlalhkuqv6c7j